PepCompass: Navigating peptide embedding spaces using Riemannian Geometry

Antimicrobial peptide discovery is challenged by the astronomical size of peptide space and the relative scarcity of active peptides. Generative models provide continuous latent "maps" of peptide space, but conventionally ignore decoder-induced geometry and rely on flat Euclidean metrics, rendering exploration and optimization distorted and inefficient. Prior manifold-based remedies assume fixed intrinsic dimensionality, which critically fails in practice for peptide data. Here, we introduce PepCompass, a geometry-aware framework for peptide exploration and optimization. At its core, we define a Union of $\kappa$-Stable Riemannian Manifolds $\mathbb{M}^{\kappa}$, a family of decoder-induced manifolds that captures local geometry while ensuring computational stability. We propose two local exploration methods: Second-Order Riemannian Brownian Efficient Sampling, which provides a convergent second-order approximation to Riemannian Brownian motion, and Mutation Enumeration in Tangent Space, which reinterprets tangent directions as discrete amino-acid substitutions. Combining these yields Local Enumeration Bayesian Optimization (LE-BO), an efficient algorithm for local activity optimization. Finally, we introduce Potential-minimizing Geodesic Search (PoGS), which interpolates between prototype embeddings along property-enriched geodesics, biasing discovery toward seeds, i.e. peptides with favorable activity. In-vitro validation confirms the effectiveness of PepCompass: PoGS yields four novel seeds, and subsequent optimization with LE-BO discovers 25 highly active peptides with broad-spectrum activity, including against resistant bacterial strains. These results demonstrate that geometry-informed exploration provides a powerful new paradigm for antimicrobial peptide design.

Targeted AMP generation through controlled diffusion with efficient embeddings

Deep learning-based antimicrobial peptide (AMP) discovery faces critical challenges such as low experimental hit rates as well as the need for nuanced controllability and efficient modeling of peptide properties. To address these challenges, we introduce OmegAMP, a framework that leverages a diffusion-based generative model with efficient low-dimensional embeddings, precise controllability mechanisms, and novel classifiers with drastically reduced false positive rates for candidate filtering. OmegAMP enables the targeted generation of AMPs with specific physicochemical properties, activity profiles, and species-specific effectiveness. Moreover, it maximizes sample diversity while ensuring faithfulness to the underlying data distribution during generation. We demonstrate that OmegAMP achieves state-of-the-art performance across all stages of the AMP discovery pipeline, significantly advancing the potential of computational frameworks in combating antimicrobial resistance.

Artificial intelligence-driven antimicrobial peptide discovery

Antimicrobial peptides (AMPs) emerge as promising agents against antimicrobial resistance, providing an alternative to conventional antibiotics. Artificial intelligence (AI) revolutionized AMP discovery through both discrimination and generation approaches. The discriminators aid the identification of promising candidates by predicting key peptide properties such as activity and toxicity, while the generators learn the distribution over peptides and enable sampling novel AMP candidates, either de novo, or as analogues of a prototype peptide. Moreover, the controlled generation of AMPs with desired properties is achieved by discriminator-guided filtering, positive-only learning, latent space sampling, as well as conditional and optimized generation. Here we review recent achievements in AI-driven AMP discovery, highlighting the most exciting directions.

A generative recommender system with GMM prior for cancer drug generation and sensitivity prediction

Recent emergence of high-throughput drug screening assays sparkled an intensive development of machine learning methods, including models for prediction of sensitivity of cancer cell lines to anti-cancer drugs, as well as methods for generation of potential drug candidates. However, a concept of generation of compounds with specific properties and simultaneous modeling of their efficacy against cancer cell lines has not been comprehensively explored. To address this need, we present VADEERS, a Variational Autoencoder-based Drug Efficacy Estimation Recommender System. The generation of compounds is performed by a novel variational autoencoder with a semi-supervised Gaussian Mixture Model (GMM) prior. The prior defines a clustering in the latent space, where the clusters are associated with specific drug properties. In addition, VADEERS is equipped with a cell line autoencoder and a sensitivity prediction network. The model combines data for SMILES string representations of anti-cancer drugs, their inhibition profiles against a panel of protein kinases, cell lines biological features and measurements of the sensitivity of the cell lines to the drugs. The evaluated variants of VADEERS achieve a high r=0.87 Pearson correlation between true and predicted drug sensitivity estimates. We train the GMM prior in such a way that the clusters in the latent space correspond to a pre-computed clustering of the drugs by their inhibitory profiles. We show that the learned latent representations and new generated data points accurately reflect the given clustering. In summary, VADEERS offers a comprehensive model of drugs and cell lines properties and relationships between them, as well as a guided generation of novel compounds.